Contact information
Type
Scientific
Primary contact
Dr John Marsden
ORCID ID
Contact details
Institute of Psychiatry
King's College London
PO Box 048
4 Windsor Walk
London
SE5 8AF
United Kingdom
-
J.Marsden@iop.kcl.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
V#1, 10/01/06
Study information
Scientific title
An evaluation of a brief assessment-led intervention with young non-injecting drug users
Acronym
Study hypothesis
That participants receiving a brief assessment-led intervention would at 3 months follow-up have a lower mean frequency of cannabis use, cocaine use, crack cocaine use and MDMA (3,4 methylenedioxymethamphetamine; Ecstasy) use combined than delayed assessment control participants
Ethics approval
King's College London, 17/10/2005, ref: 05/Q0706/219
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Prevention
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Substance misuse
Intervention
Experimental: A brief assessment-led intervention
a. Drugs and Lifestyle Assessment
b. Manual guided 30 minute feedback interview
Control 1: Assessment only
Control 2: Delayed assessment
Intervention type
Behavioural
Phase
Drug names
Primary outcome measure
Combined frequency of cocaine powder use, crack cocaine use, MDMA use and cannabis use, assessed at baseline and 90 days
Secondary outcome measures
The following were assessed at baseline and 90 days:
1. Typical intensity of cannabis use, cocaine use, crack cocaine use and MDMA use at 90 days
2. Drug dependency: Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) Personality Disorders (Structured Clinical Interview for DSM-IV Axis II Personality Disorders; SCID-II)
3. Alcohol frequency and intensity
4. Hazardous drinking: The Alcohol Use Disorders Identification Test (AUDIT)
5. General health: EQ-5D A multi-dimensional Quality of Health Instrument (EurQol)
6. Psychological health: General Health Questionnaire (GHQ 12)
7. Engagement with health and social services
Overall trial start date
01/10/2005
Overall trial end date
29/01/2008
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. 16 to 28 years old
2. Using either cannabis, cocaine powder, crack cocaine, or MDMA on four days in previous month
3. Able speak and comprehend English
4. Written consent
Participant type
Other
Age group
Adult
Gender
Both
Target number of participants
255
Total final enrolment
342
Participant exclusion criteria
1. In contact with a drug/alcohol treatment agency in previous 12 months
2. Used opiates more than 30 days in the previous 90 days or in the previous 48 hours before interview
3. Injected more than once in the last 12 months and no more than ten times lifetime
4. Receiving specialist treatment for a mental health problem
5. Participated in a similar research study in the previous 12 months
Recruitment start date
01/10/2005
Recruitment end date
29/01/2008
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Institute of Psychiatry
London
SE5 8AF
United Kingdom
Sponsor information
Organisation
King's College London (UK)
Sponsor details
Institute of Psychiatry
Kings College London
4 Windsor Walk
London
SE5 8AF
United Kingdom
-
gill.lambert@iop.kcl.ac.uk
Sponsor type
University/education
Website
Funders
Funder type
Government
Funder name
Department of Health of England & Wales, Drug Misuse Research Initiative (Phase 2) (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2006 results in https://pubmed.ncbi.nlm.nih.gov/16771893/ (added 06/08/2020)